Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vatalanib + Imatinib in Refractory AML, AMM, and CML-BP
NCT00088231Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2004
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vatalanib in acute myeloid leukemia (AML), primary myelofibrosis (PMF), chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2004; status: completed.
02
Drugs
vatalanib
03
Conditions
acute myeloid leukemia (AML)primary myelofibrosis (PMF)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00088231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088231.